Navigation Links
BioMS Medical warrant extension
Date:3/2/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, March 2 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that effective on March 16, 2009 the exercise term of 11,500,000 share purchase warrants, each of which entitles the holder to purchase one Class A common share at a price of $5.00 per share, will be extended from March 23, 2009 to December 31, 2009.

On March 18, 2008, BioMS Medical's Board of Directors passed a resolution to extend 10,514,000 of the warrants, the portion held by warrant holders who are at arm's length to the Company. At the Company's annual general meeting held on May 9, 2008, the shareholders holding a majority of the Class A common shares, excluding the votes attached to Class A common shares held by insiders whose warrants were being amended, approved the extension for the remaining 986,000 warrants held by insiders.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Weeks after hosting a carpal tunnel syndrome ... Fitzmaurice, hand surgeon and founder of the Fitzmaurice Hand Institute, has announced the addition ... is a state-of-the-art technology and only 1 of about 3 currently available in the ...
(Date:5/27/2016)... Jersey and READING, ... -- Indegene ( http://www.indegene.com ), ... marketingorientierten Lösungen für die Life-Science-Branche, Pharmaunternehmen und ... bekannter weltweiter Anbieter von innovativen wissenschaftlichen Support-Services ... des Starts von IntraScience heute den Ausbau ...
(Date:5/26/2016)... ISELIN, New Jersey and ... -- Indegene ( http://www.indegene.com ), a ... solutions to life science, pharmaceutical and healthcare organisations ... provider of innovative scientific support throughout the product ... alliance with the launch of IntraScience. ...
(Date:5/26/2016)... ... May 26, 2016 , ... After several promising treatments in ... the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient ... this year following FDA approval of a second application for a single patient, ...
Breaking Biology Technology:
(Date:3/17/2016)... 2016 ABI Research, the leader in ... biometrics market will reach more than $30 billion ... 2015. Consumer electronics, particularly smartphones, continue to boost ... to reach two billion shipments by 2021 at ... , Research Analyst at ABI Research. "Surveillance is ...
(Date:3/14/2016)... http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ( ... --> DERMALOG, le leader de l,innovation ... d,empreintes digitales pour l,enregistrement des réfugiés en Allemagne. ... produire des cartes d,identité aux réfugiés. DERMALOG dévoilera ...
(Date:3/10/2016)...   Unisys Corporation (NYSE: UIS ) today ... is testing its biometric identity solution at the Otay Mesa ... help identify certain non-U.S. citizens leaving the country. ... help determine the efficiency and accuracy of using biometric technologies ... run until May 2016. --> the United ...
Breaking Biology News(10 mins):